- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02870374
For a Better Interpretation of Quality of Life Scores of Kidney Transplant Patients: Determination of the Minimum Significant Change RetransQol (ReTransQol)
August 12, 2016 updated by: Assistance Publique Hopitaux De Marseille
The project team developped and validated a French patient-based health-related quality of life instrument in kidney transplant: the QoL Retrans.
The aim of the study is to determine the minimum significant change of the valdiated tool: ReTransQol
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
2000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Marseille, France, 13354
- Assistance Publique Hôpitaux de Marseille
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Kidneys transplanted patients
Description
Inclusion Criteria:
- Patient with a transplant kidney
Exclusion Criteria:
- Patient not able to answer survey
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of change in quality of life in kidneys transplantation patients using ReTransQol
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Stéphanie GENTILE, MD/PhD, Assistance Publique Hôpitaux de Marseille
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (ACTUAL)
March 1, 2015
Study Completion (ANTICIPATED)
January 1, 2017
Study Registration Dates
First Submitted
August 12, 2016
First Submitted That Met QC Criteria
August 12, 2016
First Posted (ESTIMATE)
August 17, 2016
Study Record Updates
Last Update Posted (ESTIMATE)
August 17, 2016
Last Update Submitted That Met QC Criteria
August 12, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- 2012-15
- 2012-A00634-39 (OTHER: Ansm)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidneys Transplantation
-
University of Medicine and Dentistry of New JerseyWithdrawnDecreased Vascular Flow to KidneysUnited States
-
University Hospital, BordeauxCompletedInterstitial Fibrosis/Tubular Atrophy of Transplanted KidneysFrance
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma IncCompletedHeart Transplantation | Lung Transplantation | Pancreas (Including SPK) TransplantationFrance, United Kingdom, Taiwan, Belgium, Italy, Austria
Clinical Trials on Answering specific quality of life questionnaire in kidneys transplantation population
-
Assiut UniversityNot yet recruitingSleep Disturbance | Postmenopausal Symptoms
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedCystinuria | Primary Hyperoxaluria | Dent Disease | Adenine Phosphoribosyl Transferase DeficiencyUnited States, Iceland
-
Uskudar State HospitalCompleted
-
Istanbul University - Cerrahpasa (IUC)Scientific Research Project Coordination Unit of Istanbul University-CerrahpasaActive, not recruitingCardiovascular Diseases | Hot Flashes | Sleep | Menopause | Epigenetics | DNA MethylationTurkey
-
Northumbria UniversityRoyal Hospital ChelseaCompletedQuality of Life | Aging WellUnited Kingdom
-
Institut du Cancer de Montpellier - Val d'AurelleNot yet recruiting
-
Freeman-Sheldon Research Group, Inc.TerminatedCraniofacial Abnormalities | Arthrogryposis | Freeman-Sheldon Syndrome | Arthrogryposis Distal Type 2A | Whistling Face Syndrome | Craniocarpotarsal Dysplasia | Craniocarpotarsal Dystrophy | Freeman-Sheldon Syndrome Variant | Sheldon-Hall Syndrome | Arthrogryposis Distal Type 2B | Gordon Syndrome | Arthrogryposis... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Non-Neoplastic Hematologic and Lymphocytic DisorderUnited States
-
University Hospital, ToulouseRecruiting
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Psychosocial Effects of Cancer and Its Treatment | Myelodysplastic/Myeloproliferative Neoplasms | Therapy-related ToxicityUnited States